Co-Authors
This is a "connection" page, showing publications co-authored by RAMONA DADU and MARIE-CLAUDE HOFMANN.
Connection Strength
0.721
-
Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance. Front Endocrinol (Lausanne). 2023; 14:1176731.
Score: 0.236
-
Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors. Thyroid. 2020 09; 30(9):1288-1296.
Score: 0.190
-
Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study. Thyroid. 2023 04; 33(4):484-491.
Score: 0.058
-
Novel Anaplastic Thyroid Cancer PDXs and Cell Lines: Expanding Preclinical Models of Genetic Diversity. J Clin Endocrinol Metab. 2021 10 21; 106(11):e4652-e4665.
Score: 0.053
-
Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma. Thyroid. 2021 08; 31(8):1235-1243.
Score: 0.051
-
Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. JAMA Oncol. 2020 09 01; 6(9):1397-1404.
Score: 0.049
-
Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma. JCO Precis Oncol. 2018 Nov; 2:1-11.
Score: 0.043
-
Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. Thyroid. 2018 07; 28(7):945-951.
Score: 0.042